Rolling Returns
Eris Lifesciences Ltd.
Every 7-year stretch ERIS has been through — 27 of them, each starting a month after the last. The median returned 12.5% a year, the worst 7.2%, the best 20.2%. A single headline CAGR hides all of that.
Every Holding Period
A rolling window is every possible start date, not one. A five-year window starting in January is a different investment from one starting in February, and over twenty years there are a couple of hundred of them. What follows is the full spread of what each holding period actually produced.
Across 99 separate 1-year holding periods, the median returned 16.2% a year. The worst lost 47.7% a year and the best made 73.7%.
Worst start: August 2018 — -47.7% a year for the 1 years that followed.
Best start: May 2024 — 73.7% a year.
Against the Nifty 50: ERIS came out ahead in 53.5% of the 99 windows both series cover.
Across 75 separate 3-year holding periods, the median returned 15.5% a year. The worst lost 12.9% a year and the best made 39.2%.
Worst start: November 2017 — -12.9% a year for the 3 years that followed.
Best start: July 2022 — 39.2% a year.
Against the Nifty 50: ERIS came out ahead in 46.7% of the 75 windows both series cover.
Across 51 separate 5-year holding periods, the median returned 12.9% a year. The worst lost 5.8% a year and the best made 31.8%.
Worst start: March 2018 — -5.8% a year for the 5 years that followed.
Best start: March 2020 — 31.8% a year.
Against the Nifty 50: ERIS came out ahead in 52.9% of the 51 windows both series cover.
Across 27 separate 7-year holding periods, the median returned 12.5% a year. Not one of them ended in a loss — the weakest still compounded at 7.2% a year.
Worst start: January 2018 — 7.2% a year for the 7 years that followed.
Best start: August 2019 — 20.2% a year.
Against the Nifty 50: ERIS came out ahead in 44.4% of the 27 windows both series cover.
Windows step forward one month at a time and are measured on month-end adjusted closing prices, so dividends are treated as reinvested. Overlapping windows share months by construction — that is what makes the spread a description of this stock's history rather than a sample of independent trials.
Against The Index
Beating an index once is a result. Beating it across most of the periods an investor could have picked is a pattern. Over 7-year windows, ERIS finished ahead of the Nifty 50 in 44.4% of the 27 periods both series cover.
1-year windows
Ahead in 53.5% of 99 periods.
3-year windows
Ahead in 46.7% of 75 periods.
5-year windows
Ahead in 52.9% of 51 periods.
7-year windows
Ahead in 44.4% of 27 periods.
Each window is compared against the index over the identical calendar months, on the same adjusted basis — not against an assumed rate of return.
How This Is Calculated
Windows step forward one month at a time, so they share most of their months with each other. That is what makes this a description of ERIS's actual history rather than a set of independent trials — and why the spread should not be read as a probability.
Measured on month-end closing prices adjusted for dividends and splits, so dividends count as reinvested. A window that opened or closed mid-month would differ a little in either direction.
ERISis in today's Nifty 500 universe. Companies that delisted or collapsed are not on this site at all, so the worst outcome shown here is the worst among the survivors.
Measured on data to 2026-08-31, from 2017-06-01. Full definitions are on our methodology page.
HELP CENTER
Everything you need to know about this page and the data presented.
Over 7 years, Eris Lifesciences Ltd. has been through 27 separate 7 years holding periods — one starting every month. The median returned 12.5% a year, the worst 7.2% and the best 20.2%. A rolling return measures every possible start date instead of one, which is why it answers a question a single headline CAGR cannot: how much the outcome depended on when you happened to buy.
No — not in any of the 27 7 years periods the record covers. The weakest of them still compounded at 7.2% a year. That is a statement about the past, not a guarantee about any future 7 years, and it is measured only over the years Eris Lifesciences Ltd. has been listed.
-5.8% a year, for the five years beginning March 2018. For contrast the best 5 years returned 31.8% a year, starting March 2020, and the median across all 51 periods was 12.9%. The gap between those two numbers is the part of the outcome that came down to timing rather than to the company.
On this record, yes. 1 year outcomes ranged from -47.7% to 73.7% a year — a spread of 121.3%. 7 years outcomes ranged from 7.2% to 20.2%, a spread of 13.0%. Longer holding periods narrowed the range of results, which is the usual pattern and the reason this page publishes every window rather than one. Narrowing the range is not the same as removing the risk.
In 44.4% of the 27 7 years periods both series cover. Each window is compared against the index over the identical months, not against an assumed index return, so the comparison is a like-for-like record rather than a model.
Windows step forward one month at a time on month-end closing prices adjusted for dividends and stock splits, so dividends are treated as reinvested. A window length is only published once there are at least twelve complete windows behind it — fewer than that describes an anecdote, not a distribution. Overlapping windows share months by construction, which is what makes this a description of the actual history of Eris Lifesciences Ltd. rather than a sample of independent trials. Companies that delisted are not on this site at all, a survivorship bias worth holding in mind.
That is not a question this page answers, and we do not make recommendations. What it can show you is the full range of what every holding period in the listed history of Eris Lifesciences Ltd. actually produced — including the worst ones, which most performance figures leave out. Those are records of what happened, not forecasts. A stock that never had a losing decade may still have one, and holding a single company is a materially different risk from holding an index.
Explore Further
ERIS drawdowns and all-time high
The worst fall on record, how long recovery took, and how far the price sits below its peak.
ERIS SIP returns
What a monthly investment would have produced, backtested rather than assumed.
ERIS overview
Price history, wealth journey and how it compares with the index.
Rolling returns for every stock
Run the same question against any company we track.
ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser. Everything on this page is a record of what historical prices did, not a projection and not a recommendation. Past performance does not guarantee future returns. See our methodology and disclaimer.